Last reviewed · How we verify
Implanon®
Implanon® releases a steady dose of the progestin etonogestrel subdermally to prevent ovulation and thicken cervical mucus, providing long-acting reversible contraception.
Implanon® releases a steady dose of the progestin etonogestrel subdermally to prevent ovulation and thicken cervical mucus, providing long-acting reversible contraception. Used for Long-acting reversible contraception in women of reproductive age.
At a glance
| Generic name | Implanon® |
|---|---|
| Also known as | Nexplanon® |
| Sponsor | FHI 360 |
| Drug class | Progestin-only contraceptive |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | FDA-approved |
Mechanism of action
Implanon® is a subdermal implant containing etonogestrel, a synthetic progestin that suppresses the luteinizing hormone (LH) surge required for ovulation. The implant provides continuous hormone release over three years, also increasing cervical mucus viscosity to impede sperm transport. This dual mechanism achieves contraceptive efficacy exceeding 99%.
Approved indications
- Long-acting reversible contraception in women of reproductive age
Common side effects
- Irregular bleeding or amenorrhea
- Headache
- Breast tenderness
- Mood changes
- Insertion site pain or infection
- Weight gain
Key clinical trials
- Body Composition and Sport Performance Among Young Female Soccer Players Using Subdermic Etonogestrel (EARLY_PHASE1)
- Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa (PHASE4)
- Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level
- A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED) (PHASE4)
- A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720) (PHASE3)
- Does Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year? (NA)
- Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk (PHASE4)
- Evaluation of a Subcutaneous Progestogen Implants in the Medical Management of Painful Endometriosis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Implanon® CI brief — competitive landscape report
- Implanon® updates RSS · CI watch RSS
- FHI 360 portfolio CI